Showing results (121-130 of 165) with videos related to

Sort By:
Pageof 17
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab eraC Y Cheah, D Chihara, M Ahmed, et al.
Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
British Journal of Haematology|October 16, 2020
Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched studyC K Chin, K J Lim, K Lewis, et al.
Haematologica|March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialPau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
British Journal of Cancer|July 30, 2014
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaC Y Cheah, K E Herbert, K O'Rourke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2022
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialCatherine Thieblemont, Tycel Phillips, Herve Ghesquieres, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Pageof 17